Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Breast Cancer Research

Fig. 1

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Fig. 1

Frequency of somatic PIK3CA and/or ERBB family mutations in baseline tumour biopsies from 74 patients enrolled in the TCHL clinical trial where adequate tumour was available following quality control. EGFR Epidermal growth factor receptor, ERBB3 Erb-B2 receptor tyrosine kinase 3, ERBB4 Erb-B2 receptor tyrosine kinase 4

Back to article page